{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:42:38Z","timestamp":1793353358647,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011082","name":"School of Medicine, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Calcinosis, or the deposition of insoluble calcium salts in the skin, subcutaneous tissue, fascia, tendons, and muscles, is a feared complication of juvenile dermatomyositis. Calcinosis is estimated to affect up to 40% of patients with juvenile dermatomyositis and contributes to significant disease morbidity. Calcinosis can be challenging to treat, and the most effective treatment remains unknown because of a lack of comparative studies. We aim to review the literature published in the last 5 years to summarize updates on the pathogenesis and treatment of calcinosis in juvenile dermatomyositis and describe future areas for research.<\/jats:p>","DOI":"10.3389\/fmed.2023.1155839","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T05:37:00Z","timestamp":1677735420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment"],"prefix":"10.3389","volume":"10","author":[{"given":"Caitlan S.","family":"Pinotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Dvergsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review.","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.pcl.2018.04.006","article-title":"Juvenile idiopathic inflammatory myopathies.","volume":"65","author":"Huber","year":"2018","journal-title":"Pediatr Clin North Am."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20210008","article-title":"Mitochondrial calcification.","volume":"3","author":"Duvvuri","year":"2021","journal-title":"Immunometabolism."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00974-9","article-title":"Treatment of calcinosis in juvenile dermatomyositis.","volume":"23","author":"Cinar","year":"2021","journal-title":"Curr Rheumatol Rep."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101768","article-title":"Calcinosis in dermatomyositis: origins and possible therapeutic avenues.","volume":"32","author":"Davuluri","year":"2022","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B6","first-page":"1921","article-title":"Mitochondrial ROS as a regulator of calcinosis in juvenile dermatomyositis","volume":"72","author":"Duvvuri","year":"2020","journal-title":"Arth Rheumatol"},{"key":"B7","first-page":"1437","article-title":"Mitochondrial calcification-induced inflammation in human skeletal muscle and immune cells","volume":"73","author":"Duvvuri","year":"2021","journal-title":"Arth Rheumatol"},{"key":"B8","first-page":"4838","article-title":"Mitochondrial contribution to juvenile dermatomyositis pathogenesis [abstract]","volume":"71","author":"Duvvuri","year":"2019","journal-title":"Arth Rheumatol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/art.41078","article-title":"Neutrophil extracellular traps in tissue and periphery in juvenile dermatomyositis.","volume":"72","author":"Duvvuri","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaad.2020.12.032","article-title":"Skin disease is more recalcitrant than muscle disease: a long-term prospective study of 184 children with juvenile dermatomyositis.","volume":"84","author":"Wang","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3899\/jrheum.220249","article-title":"Early abnormal nailfold capillary changes are predictive of calcinosis development in juvenile dermatomyositis.","volume":"49","author":"Nozawa","year":"2022","journal-title":"J Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0299-9","article-title":"Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.","volume":"16","author":"Orandi","year":"2018","journal-title":"Pediatr Rheumatol."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-022-00709-3","article-title":"Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new childhood arthritis and rheumatology research alliance registry.","volume":"20","author":"Neely","year":"2022","journal-title":"Pediatr Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.25259\/IJDVL_297_20","article-title":"Juvenile dermatomyositis in Thai children: retrospective review of 30 cases from a tertiary care center.","volume":"88","author":"Nitiyarom","year":"2022","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10067-016-3530-4","article-title":"Juvenile dermatomyositis: a tertiary center experience.","volume":"36","author":"Barut","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semarthrit.2020.10.007","article-title":"Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis.","volume":"51","author":"Sag","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"B17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.55563\/clinexprheumatol\/h0s7tq","article-title":"A juvenile dermatomyositis: demographics, characteristics and disease outcome in an Egyptian cohort.","volume":"40","author":"El-Garf","year":"2022","journal-title":"Clinical Exp Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12098-017-2302-8","article-title":"Profile of pediatric idiopathic inflammatory myopathies from a tertiary care center of Eastern India.","volume":"84","author":"Sarkar","year":"2017","journal-title":"Indian J Pediatr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/1756-185X.13759","article-title":"Long-term outcome in children with juvenile dermatomyositis: a single-center study from north India.","volume":"23","author":"Sharma","year":"2020","journal-title":"Int J Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.55563\/clinexprheumatol\/94btoy","article-title":"Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort.","volume":"40","author":"Horn","year":"2022","journal-title":"Clin Exp Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort.","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.810785","article-title":"Is anti-NXP2 autoantibody a risk factor for calcinosis and poor outcome in juvenile dermatomyositis patients? Case series.","volume":"9","author":"Toplak","year":"2021","journal-title":"Front Pediatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2019.06.014","article-title":"Long-term outcomes in juvenile myositis patients.","volume":"50","author":"Tsaltskan","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"B24","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.23840","article-title":"Association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis: results from the childhood arthritis and rheumatology research alliance legacy registry.","volume":"71","author":"Neely","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","article-title":"Race, income, and disease outcomes in juvenile dermatomyositis.","volume":"184","author":"Phillippi","year":"2017","journal-title":"J Pediatr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1093\/rheumatology\/key190","article-title":"Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.","volume":"57","author":"Mamyrova","year":"2018","journal-title":"Rheumatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis.","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash.","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0199-4","article-title":"Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).","volume":"15","author":"Orandi","year":"2017","journal-title":"Pediatr Rheumatol Online J."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0174-0","article-title":"Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the childhood arthritis and rheumatology research alliance in North America.","volume":"15","author":"Spencer","year":"2017","journal-title":"Pediatr Rheumatol Online J."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4073879","article-title":"Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl.","volume":"2020","author":"Sukumaran","year":"2020","journal-title":"Case Rep Rheumatol."},{"key":"B32","article-title":"Abatacept as adjunct therapy for the calcinosis of juvenile dermatomyositis: a single-center experience.","volume":"69","author":"Deguzman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s13312-020-1712-2","article-title":"Pamidronate in treatment of calcinosis in juvenile dermatomyositis.","volume":"57","author":"Giri","year":"2020","journal-title":"Indian Pediatr."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-252814","article-title":"Bisphosphonate therapy for juvenile dermatomyositis-associated calcinosis and metaphyseal zebra lines.","volume":"15","author":"Janarthanan","year":"2022","journal-title":"BMJ Case Rep."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15960","article-title":"Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy.","volume":"35","author":"Agud-Dios","year":"2022","journal-title":"Dermatol Ther."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain."},{"key":"B37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1093\/rheumatology\/keaa360","article-title":"A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate.","volume":"59","author":"S\u00f6zeri","year":"2020","journal-title":"Rheumatology."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib.","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain."},{"key":"B40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.24953\/turkjped.2019.05.018","article-title":"Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil.","volume":"61","author":"\u00c7akan","year":"2019","journal-title":"Turk J Pediatr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4236\/ojra.2017.71002","article-title":"Effectiveness of rituximab therapy on severe calcinosis in 4 children with juvenile dermatomyositis.","volume":"7","author":"Alhemairi","year":"2017","journal-title":"Open J Rheumatol Autoimmune Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.reumae.2018.06.003","article-title":"Treatment with rituximab in juvenile dermatomyositis: effect on calcinosis.","volume":"16","author":"Vargas Lebr\u00f3n","year":"2020","journal-title":"Reumatol Cl\u00edn."},{"key":"B44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jbspin.2016.10.009","article-title":"Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: report of four cases.","volume":"84","author":"Mageau","year":"2017","journal-title":"Joint Bone Spine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/bjd.15783","article-title":"Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis.","volume":"178","author":"Song","year":"2018","journal-title":"Br J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1111\/pde.13868","article-title":"Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate.","volume":"36","author":"Topham","year":"2019","journal-title":"Pediatr Dermatol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-022-04332-8","article-title":"Use of adalimumab in a child with juvenile dermatomyositis and calcinosis.","volume":"89","author":"Jin","year":"2022","journal-title":"Indian J Pediatr."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm1809669","article-title":"Calcinosis in juvenile dermatomyositis.","volume":"381","author":"Li","year":"2019","journal-title":"N Eng J Med."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00690-x","article-title":"Nodular regenerative hyperplasia of the liver in juvenile dermatomyositis.","volume":"20","author":"Lanis","year":"2022","journal-title":"Pediatr Rheumatol Online J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5978\/islsm.14-RE-01","article-title":"The role of the CO2 laser and fractional CO2 laser in dermatology.","volume":"23","author":"Omi","year":"2014","journal-title":"Laser Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/ijd.13720","article-title":"Abstracts - Oral and poster presentations from the XII international congress of dermatology April 18-22, 2017 - Buenos Aires, Argentina.","volume":"56","author":"Zarate","year":"2017","journal-title":"Int J Dermatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00198-022-06501-z","article-title":"Regression of calcinosis cutis after inkless tattoo in a patient with dermatomyositis: therapeutic potential of microneedling.","volume":"33","author":"Motlaghzadeh","year":"2022","journal-title":"Osteoporos Int."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-0402-x","article-title":"Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the childhood arthritis & rheumatology research alliance legacy registry.","volume":"18","author":"Tory","year":"2020","journal-title":"Pediatr Rheumatol Online J."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00615-0","article-title":"Favorable outcomes with reduced steroid use in juvenile dermatomyositis.","volume":"19","author":"Orandi","year":"2021","journal-title":"Pediatr Rheumatol Online J."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/ar4198","article-title":"Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?","volume":"15","author":"Tansley","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3899\/jrheum.220248","article-title":"Seronegative polyarthritis in association with anti-NXP2 antibodies: a case series.","volume":"50","author":"Mourot","year":"2022","journal-title":"J Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1155839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T05:37:06Z","timestamp":1677735426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1155839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":57,"alternative-id":["10.3389\/fmed.2023.1155839"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1155839","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"article-number":"1155839"}}